Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus
You may also be interested in...
REALITY Trial Investigators’ Expectations May Have Been Unrealistic – JAMA
Investigators in the Johnson & Johnson-sponsored REALITY drug-eluting stent trial should not have expected large differences in outcomes between J&J's Cypher and Boston Scientific's Taxus, according to an editorial in the Feb. 22 issue of the Journal of the American Medical Association
REALITY Trial Investigators’ Expectations May Have Been Unrealistic – JAMA
Investigators in the Johnson & Johnson-sponsored REALITY drug-eluting stent trial should not have expected large differences in outcomes between J&J's Cypher and Boston Scientific's Taxus, according to an editorial in the Feb. 22 issue of the Journal of the American Medical Association
Warning Letter Should Not Hinder Taxus Liberté Approval – Boston Scientific
Boston Scientific estimates it will be ready by June for FDA to re-inspect its facilities to confirm that the quality-control problems cited in a sweeping Jan. 25 warning letter have been fixed